Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $604.8 billion.

  • Addex Therapeutics' Net Cash Flow fell 7305.46% to $604.8 billion in Q2 2025 from the same period last year, while for Sep 2025 it was $712.5 billion, marking a year-over-year decrease of 5433.74%. This contributed to the annual value of -$708648.2 for FY2024, which is 7672.66% up from last year.
  • As of Q2 2025, Addex Therapeutics' Net Cash Flow stood at $604.8 billion, which was down 7305.46% from -$556.9 billion recorded in Q1 2025.
  • Addex Therapeutics' Net Cash Flow's 5-year high stood at $2313.4 billion during Q4 2023, with a 5-year trough of -$2764.5 billion in Q3 2023.
  • For the 4-year period, Addex Therapeutics' Net Cash Flow averaged around -$4.2 billion, with its median value being -$2.4 million (2022).
  • Examining YoY changes over the last 5 years, Addex Therapeutics' Net Cash Flow showed a top increase of 6877117444.11% in 2023 and a maximum decrease of 17849516318.17% in 2023.
  • Addex Therapeutics' Net Cash Flow (Quarter) stood at -$3.4 million in 2022, then soared by 68771174.44% to $2313.4 billion in 2023, then tumbled by 71.27% to $664.6 billion in 2024, then fell by 9.0% to $604.8 billion in 2025.
  • Its Net Cash Flow was $604.8 billion in Q2 2025, compared to -$556.9 billion in Q1 2025 and $664.6 billion in Q4 2024.